Company intelligence / Profile preview

ACRO Biomedical

Kaohsiung City, Taiwanacrobiomedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

ACRO Biomedical has developed several collagen-based medical devices that have received regulatory approvals in the U.S., Taiwan, and Singapore. Their ABCcolla® Collagen ADM Scaffold is U.S. FDA 510(k) cleared. The company has demonstrated clinical success with the world’s first canine corneal transplantation using their technology and continues to expand its product portfolio for regenerative medicine applications.

Therapeutic areas: OtherCardiovascularRheumatologyOphthalmology
Modalities: BiomaterialsCollagen ScaffoldsAcellular MatricesXenograft biomaterials
Industry: Implantable Medical Devices

Partnerships

Exclusive distributorship agreement with Marubeni for all product lines in JapanCollaboration with Animal Technology Laboratories of Agricultural Technology Research Institute (ATRI), Taiwan

Beyond the preview

Go deeper on ACRO Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACRO Biomedical.

Explore the full profile